中国实用内科杂志2011，Vol.31Issue(11)：862-864,3.
格列美脲与格列苯脲治疗2型糖尿病Meta分析
A meta-analysis on treatment of type 2 diabetes mellitus with glimepiride vs glibenclamide
贾贺 1韩萍1
作者信息
- 1. 中国医科大学附属盛京医院内分泌科,沈阳110004
- 折叠
摘要
Abstract
Objective To assess therapeutic efficacy of glimepiride vs glibenclamide in treatment of type 2 diabetes mellitus ( T2DM). Methods We searched medical literatures in several databases including the PubMed,CNKI,Wanfang and VIP databases. The quality of the studies was evaluated according to criteria in Co-chrane systematic reviews. Meta-analysis of these studies was completed with the Review Manager (version 4. 2) software package. Results Nine prospective RCTs were included in the analysis. The results showed that there were no differences between two groups in reducing glycosylated hemoglobin,fasting and postprandial plasma glucose , cholesterol and triglyceride ( P > 0.05). In patients with the same glucose level, glimepiride was associated with significantly less increase in fasting and postprandial plasma insulin (P <0. 05), and lower incidence of hy-poglycemia as compared with glibenclamide (P < 0. 05). In addition, glimepiride showed better performance than glibenclamide in reducing BMI (P < 0. 05). Conclusion Compared with glibenclamide, glimepiride is as potent in reducing blood glucose and shows additional benefits with improved insulin resistance and lower incidence of BMI. Therefore,glimepiride is a safe and effective agent for treatment of type 2 diabetes mellitus.关键词
格列美脲/格列苯脲/2型糖尿病Key words
glimepiride/glibenclamide/type 2 diabetes mellitus分类
医药卫生引用本文复制引用
贾贺,韩萍..格列美脲与格列苯脲治疗2型糖尿病Meta分析[J].中国实用内科杂志,2011,31(11):862-864,3.
